| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of the proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC3) genes. This represents an important step forward for the RNAi field as it is the first clinical candidate to target two genes simultaneously in one molecule, enabled by Arrowhead's innovative and proprietary Targeted RNAi Molecule (TRiMTM) platform.
Mixed hyperlipidemia is a highly prevalent disorder characterized by elevated low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels and is a major risk factor for ASCVD, which is the leading cause of mortality worldwide and associated with substantial morbidity and healthcare costs. Despite the efficacy of LDL-C-lowering therapies in reducing ASCVD risk, there remains substantial residual risk in patients with mixed hyperlipidemia.
"Arrowhead is at the forefront of innovation in the RNAi field and the expansion of the TRiMTM platform to now include a clinical stage candidate that can potentially silence expression of two genes in one RNAi molecule further reinforces our leadership position. ARO-DIMER-PA silences the PCSK9 and APOC3 genes, which both together have substantial clinical validation as important targets for reducing LDL-cholesterol, triglycerides, and total atherogenic lipoproteins. We see this as a promising profile with the potential to reduce the high levels of residual risk of ASCVD that persist," said Chris Anzalone, Ph.D., President and CEO at Arrowhead. "The robust design of our Phase 1/2a clinical study, which is evaluating single and multiple doses directly in patients with mixed hyperlipidemia, may yield important insights into the potential of ARO-DIMER-PA in 2026. With our upcoming November 18, 2025, PDUFA date for plozasiran, which represents our first potential commercial product, and an ongoing Phase 3 for an additional candidate, zodasiran in homozygous familial hypercholesterolemia (HoFH), the addition of ARO-DIMER-PA fits well strategically with our growing commercial focus on RNAi therapeutics in the cardiometabolic therapeutic area."
An application for approval to initiate the clinical trial was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. Pending clearance, Arrowhead intends to proceed with a Phase 1/2a, randomized, double-blind, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and effects on LDL-C and TGs of a single-dose of ARO-DIMER-PA (Part 1) and multiple doses of ARO-DIMER-PA (Part 2) in up to 78 adult subjects with mixed hyperlipidemia.
ARO-DIMER-PA is a dual functional RNAi molecule designed to silence expression of the PCSK9 and APOC3 genes in hepatocytes. Prior clinical experience with other investigational and approved agents suggests that PCSK9 and APOC3 inhibition may lead to robust reductions in LDL-C, TGs, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins.
Preclinical data on ARO-DIMER-PA were previously presented at the National Lipid Association (NLA) 2025 Annual Scientific Sessions and may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
Posted In: ARWR
